BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21220503)

  • 1. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
    Tsimberidou AM; Takimoto CH; Moulder S; Uehara C; Mita M; Mita A; Urban P; Tan E; Wang Y; Vining D; Kurzrock R
    Mol Cancer Ther; 2011 Jan; 10(1):209-17. PubMed ID: 21220503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
    Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
    Tsimberidou AM; Lewis N; Reid T; Burris H; Urban P; Tan EY; Anand S; Uehara C; Kurzrock R
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1507-16. PubMed ID: 21499896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
    Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
    Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
    Nayak L; DeAngelis LM; Robins HI; Govindan R; Gadgeel S; Kelly K; Rigas JR; Peereboom DM; Rosenfeld SS; Muzikansky A; Zheng M; Urban P; Abrey LE; Omuro A; Wen PY
    Cancer; 2015 Dec; 121(23):4165-72. PubMed ID: 26308485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
    Schelman W; Morgan-Meadows S; Bailey H; Holen K; Thomas JP; Eickhoff J; Brandon H; Oliver K; Alberti D; Wilding G
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):727-33. PubMed ID: 18172649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
    Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
    J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of patupilone in patients with advanced solid tumor malignancies.
    Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
    Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
    Melichar B; Casado E; Bridgewater J; Bennouna J; Campone M; Vitek P; Delord JP; Cerman J; Salazar R; Dvorak J; Sguotti C; Urban P; Viraswami-Appanna K; Tan E; Tabernero J
    Br J Cancer; 2011 Nov; 105(11):1646-53. PubMed ID: 22027708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.
    Fogh S; Machtay M; Werner-Wasik M; Curran WJ; Bonanni R; Axelrod R; Andrews D; Dicker AP
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1009-16. PubMed ID: 19879067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
    Mani S; McDaid H; Hamilton A; Hochster H; Cohen MB; Khabelle D; Griffin T; Lebwohl DE; Liebes L; Muggia F; Horwitz SB
    Clin Cancer Res; 2004 Feb; 10(4):1289-98. PubMed ID: 14977827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.
    Hussain A; DiPaola RS; Baron AD; Higano CS; Tchekmedyian NS; Johri AR
    Ann Oncol; 2009 Mar; 20(3):492-7. PubMed ID: 19087985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
    Becquet M; Laborde L; Texier C; Sterker D; Gschwind HP; Pfaar U; Wartmann M; O'Reilly TM; McSheehy PM
    Anticancer Drugs; 2018 Aug; 29(7):691-701. PubMed ID: 29734209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
    Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.